| abstract |
Biomarkers and agents for repeated implantation failure, the biomarkers comprising one or more of G0 annotated at GO:0030286, GO:0003777, GO:0007018, GO:0016887, GO:0005874, GO:0005858, GO:0060285, GO:0005871, or/and KEGG annotated pathway-associated genes under hsa 05016; biomarkers for characterizing, diagnosing, or classifying "subclinical hypopituitarism" patients who have failed repeated implants, and for predicting the therapeutic responsiveness of patients who have failed repeated implants to a luteal phase support therapy; also provided are agents for recurrent implantation failure, a luteinizing agent which is an estrogen and/or progestin modulating agent, and a luteinizing activity-related agent which is a human chorionic gonadotropin administered after embryo implantation, wherein the subject with recurrent implantation failure has (1) no clinical pregnancy observed for three or more consecutive high-quality embryo transplants, (2) an undefined etiology of RIF, and (3) a blood luteinizing hormone level of not more than 5IU/L on day 2 (day D2) after ovulation. |